Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Sponsored by Amgen
About this study
Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
Where this study is enrolling (2)
- Call 480-360-4000
Arizona Clinical Trials
Chandler, Arizona
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
- I'm interested
Biopharma Informatic, LLC
Houston, Texas
Who can participate
Inclusion criteria
- ✓Body Mass Index (BMI) ≥ 25 at screening.
- ✓Weight loss of ≥ 10% on weekly GLP-1 RA.
- ✓Stable body weight.
- ✓Stable dose of GLP-1RA.
- ✓Stable gastrointestinal (GI) tolerability.
- ✓Contraception for females.
- ✓Willingness to follow trial procedures for the duration of the trial.
Exclusion criteria
- ✕Obesity induced by other endocrine disorders (ex: Cushing's syndrome).
- ✕Previous or planned surgical, endoscopic or device-based treatment for obesity.
- ✕History of malignancy.
- ✕Type 1/Type 2 diabetes mellitus (DM).
- ✕Family or personal history of medullary thyroid cancer.
- ✕Previous participation in a Maridebart Cafraglutide trial.
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.